Glaxo and Genmab drop IV version of MS immune drug
Glaxo and Genmab drop IV version of MS immune drug
GlaxoSmithKline PLC and Genmab A/S will end the development of an intravenous form of a drug intended to treat autoimmune diseases like lupus and multiple sclerosis, and focus on an injectable version.
The companies said an injectable version of Arzerra (ofatumumab) should be more convenient for patients and have fewer side effects. The drug can also be used to treat rheumatoid arthritis...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 1 Replies
- 1991 Views
-
Last post by goellerc
-
- 0 Replies
- 1208 Views
-
Last post by ElliotB
-
- 3 Replies
- 5057 Views
-
Last post by NHE
-
- 1 Replies
- 1614 Views
-
Last post by ElliotB
-
- 0 Replies
- 1255 Views
-
Last post by DIM
-
- 0 Replies
- 654 Views
-
Last post by NHE
-
- 0 Replies
- 1723 Views
-
Last post by NHE
-
- 1 Replies
- 3352 Views
-
Last post by Tif
-
- 0 Replies
- 294 Views
-
Last post by DIM